MRX34 as the first anticancer miRNA drug has entered Phase I clinical trials in patients with primary liver cancer and metastatic HCC [10–12], which suggested the prospects of applying therapeutic miRNAs to HCC. The gene discussed is IL1RAPL1; the disease is hepatocellular carcinoma.